Teva Pharmaceutical Industries (TEVA) Intangibles (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Intangibles came in at $3.4 billion in Q2 2026, down 16.78% YoY from $4.1 billion in Q2 2025, and down 4.49% on a QoQ basis from $3.6 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Intangibles (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Intangibles data on file, last reported at $3.4 billion in Q2 2026.
- Quarterly Intangibles fell 16.78% year-over-year to $3.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.4 billion (down 16.78% YoY) and the FY2025 annual result came in at $3.8 billion, down 14.42% from the prior year.
- Intangibles fell to $3.4 billion in Q2 2026, from $3.6 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $7.1 billion in Q1 2022 to a low of $3.4 billion in Q2 2026.
- A 5-year average of $5.1 billion and a median of $5.0 billion in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2022 — Intangibles retreated 18.37% — and 2023, when it retreated 13.58%.
- Tracing TEVA's Intangibles over 5 years: stood at $6.3 billion in 2022, then fell by 14.08% to $5.4 billion in 2023, then declined by 17.99% to $4.4 billion in 2024, then declined by 14.42% to $3.8 billion in 2025, then retreated by 8.83% to $3.4 billion in 2026.
- The last three Intangibles figures came in at $3.4 billion (Q2 2026), $3.6 billion (Q1 2026), and $3.8 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 3.45 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 918.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 21.28 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 13.68 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 2.23 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 3.20 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 1.12 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 1.80 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.45 Bn |
| Mar 31, 2026 | 3.61 Bn |
| Dec 31, 2025 | 3.78 Bn |
| Sep 30, 2025 | 3.94 Bn |
| Jun 30, 2025 | 4.14 Bn |
| Mar 31, 2025 | 4.19 Bn |
| Dec 31, 2024 | 4.42 Bn |
| Sep 30, 2024 | 4.76 Bn |
| Jun 30, 2024 | 4.85 Bn |
| Mar 31, 2024 | 5.06 Bn |
| Dec 31, 2023 | 5.39 Bn |
| Sep 30, 2023 | 5.53 Bn |
| Jun 30, 2023 | 5.74 Bn |
| Mar 31, 2023 | 5.96 Bn |
| Dec 31, 2022 | 6.27 Bn |
| Sep 30, 2022 | 6.39 Bn |
| Jun 30, 2022 | 6.70 Bn |
| Mar 31, 2022 | 7.12 Bn |
| Dec 31, 2021 | 7.47 Bn |
| Sep 30, 2021 | 7.83 Bn |